Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease

Br J Haematol. 2007 Jan;136(2):301-4. doi: 10.1111/j.1365-2141.2006.06437.x.

Abstract

This study defined the clinical features and assessed the prognosis of 47 patients (17 males, 30 females, median age 63 years) with primary nodal marginal zone B-cell lymphoma. Forty-five per cent had stage IV disease. Hepatitis C virus serology was positive in 24%. According to the Follicular Lymphoma International Prognostic Index (FLIPI), 33% were classified as low-risk, 34% as intermediate-risk, and 33% as high-risk. The 5-year overall survival (OS) was 69%. In univariate analysis worse OS was associated with: FLIPI (P = 0.02), age > 60 years (P = 0.05) and raised lactate dehydrogenase (P = 0.05). In multivariate analysis, only FLIPI predicted a worse OS (P = 0.02).

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Female
  • Hepacivirus
  • Hepatitis C / complications
  • Humans
  • Immunophenotyping
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / pathology*
  • Lymphoma, B-Cell / virology
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Prednisone / administration & dosage
  • Prognosis
  • Rare Diseases / drug therapy
  • Rare Diseases / pathology*
  • Rare Diseases / virology
  • Survival Analysis
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol